Success is not always the domain of the highly educated. Bob Duggan,\na successful entrepreneur, has profited handsomely from investment in\nbiotechnology stocks. His latest investment in Summit Therapeutics\n(SMMT) has surged more than 1,000%.<\/p>\n
According to the Wall Street Journal, the surge in the\nbiopharmaceutical company\u2019s stock occurred following data from\nlate-stage trials showing that its drug Ivonescimab defeated Merck\u2019s\nblockbuster cancer drug Keytruda in patients with lung cancer.<\/p>\n
Duggan, already a billionaire prior to his Summit investment, is now\nestimated to hold a fortune of approximately US$16 billion, or around\n243.1 trillion rupiah. Nevertheless, significant challenges remain\nregarding the drug, including its performance in global trials outside\nChina, where Summit licensed Ivonescimab from Chinese biotechnology\ncompany Akeso in 2022.<\/p>\n
This is not Duggan\u2019s first success in biotechnology. Two decades ago,\nhe invested in Pharmacyclics, a company developing cancer drug\nImbruvica. After overcoming various challenges, Pharmacyclics was\neventually acquired by AbbVie for US$21 billion, establishing Duggan as\na significant figure in the industry.<\/p>\n
At 80 years old, Duggan has demonstrated that success in this\nindustry is not the exclusive domain of those with elevated academic\ncredentials. Nathan Vardi, author of \u201cFor Blood and Money,\u201d notes that\nwhilst many believe Duggan was simply fortunate, his ability to\ndetermine when to hold or exit investments has been the key to his\nsuccess.<\/p>\n
Duggan\u2019s experience across various industries, ranging from\nbread-making to robotics, has given him a distinctive perspective when\nfacing challenges. He believes that an outsider\u2019s lack of understanding,\ncombined with the intensity he brings, enables him to undertake\nunconventional steps.<\/p>\n
Ivonescimab, for instance, not only functions as a PD-1 protein\nbinder to trigger the immune system, but also inhibits VEGF protein that\nsupports tumour blood vessel growth. The drug operates through dual\nmechanisms, which is anticipated to deliver stronger effects in\ncombating cancer.<\/p>\n
However, experts caution that this dual action may present safety\nconcerns later. Given the documented side effects of drugs targeting\nVEGF, analysts await further data to ensure the drug is safe and can\nenhance patient survival.<\/p>\n
Whilst Summit possesses opportunities to compete in the US$50 billion\nPD-1 market, implementation challenges remain significant. Analysts warn\nthat success will depend heavily on proper management and effective\ntrial design strategy.<\/p>\n
As the market digests the substantial challenges facing Summit, the\ncompany\u2019s shares are expected to remain volatile and could experience\ndeclines following the post-data price surge. With all attention focused\non Ivonescimab, the future of Duggan and Summit will be closely watched\nby investors and analysts worldwide.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/college-dropout-profits-1-000-in-biotechnology-stocks-1780365634", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }